Biocryst Pharma Inc(BCRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low9.50
Day High9.50
Open:9.50
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
BioCryst (BCRX) Receives a Buy from Bank of America Securities
GlobeNewswire
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
Tipranks
BioCryst (BCRX) Receives a Buy from Wedbush
GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)
Tipranks
BioCryst Advances Rare Disease Pipeline Amid Cost Controls
GlobeNewswire
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
Tipranks
BioCryst Shareholders Approve Expanded Equity Incentive Plan
GlobeNewswire
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MarketBeat
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
MarketBeat.com
GlobeNewswire
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
Tipranks
BioCryst Earnings Call: ORLADEYO Momentum vs. Risks
GlobeNewswire
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Penumbra (PEN) and BioCryst (BCRX)
Tipranks
Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)
Tipranks
BioCryst Posts Q1 2026 Results, Maintains Growth Outlook
Motley Fool
BioCryst (BCRX) Q1 2026 Earnings Transcript
GlobeNewswire
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

Profile

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.